Optical coherence tomography in preclinical diagnosis of optic nerve disk changes after chemotherapy in children with retinoblastoma

Purpose. Using optical coherence tomography (OCT), determine the preclinical changes in optic nerve head (ONH) after chemotherapy in children with retinoblastoma (RB). Material and methods. 38 patients (76 eyes) were examined and treated: 15 girls, 23 boys with RB averagely aged 21.0 ± 1.5 months. Of these, 58 affected eyes before treatment belonged to groups А (3), В (16), С (33), D (3), and Е (3). All tumor nodes were located on the fundus outside the optic disk. The examination of these eyes was carried out on an optical coherent tomograph SOCT Copernicus 4.2 (Poland). The 58 eyes were first tested before treatment, then after 3 or 4 courses of systemic chemotherapy (CT), once again after 6 courses of systemic CT and 1–3 courses of superselective intraarterial CT and 4–9 courses of intravitreal CT. 15 healthy children (30 eyes) of the corresponding age were examined as a control. Results. After 3 courses of systemic CT, OCT determined optic neuropathy with edema in 46.6 %. Morphometric data included parapapillary retinal cystic cavities, elevation of the contour of the optic disc towards the vitreous, increased rim volume (to 0.87 ± 0.12 mm³) and average thickness of the nerve fiber layer increased to 0.39 ± 0.06 mm (p < 0.01). After combined chemotherapy we revealed the thinning of the peripapillary choroid (to 80.0 ± 3.2 μm) with no retinal edema in 34.5 %, a reduction of rim volume to 0.34 ± 0.2 mm³ and the layer of nerve fibers to 0.02 ± 0.01 mm (p < 0.01). These changes are evidences of optic nerve disc atrophy. Conclusion. OCT is an informative method of examining the optic disc in children with RB at different stages of treatment, which identifies signs of edema and symptoms of atrophy more often (respectively, by 15.6 % and 17.3 %). Preclinical diagnostics of optic disc pathology with the help of OCT allows predicting visual functions in children with RB at its early stages and developing a differentiated approach to the choice of RB treatment.

retinoblastoma, chemotherapy, optic nerve head, optical coherence tomography

1. Lumbroso B., Rispoli M. ОКТ (сетчатка, сосудистая оболочка, глаукома). Москва: Бином; 2014. [Lumbroso B., Rispoli M. OCT (retina, choroid, glaucoma). Moscow: Binom; 2014 (in Russian)].

2. Virgili G., Menchini F., Casazza G., et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst. Rev. 2015; 1: CD008081. doi: 10.1002/14651858.CD008081.pub3

3. Saakyan S.V., Panteleeva O.G., Myakoshina E.B., Sirmais O.S. Method for staging optic neuropathy accompanying endocrine ophthalmopathy by spectral optical coherence tomography. Patent RF #2535403; 2014 (in Russian).

4. Katargina L.A., Mazanova E.V., Tarasencov А.О., Ryabtsev D.I. The modern methods for diagnostics of glaucomatous optic neuropathy in the children presenting with congenital glaucoma. Rossijskaya pediatricheskaya oftal’mologija. 2012; 1: 18–21 (in Russian).

5. Brovkina A.F., Budzinskaya M.V., Stoyukhina A.S., Musatkina I.V. Precise diagnosis of choroidal hemangioma. Vestnik oftal'mologii. 2016; 4: 10–9. doi: 10.17116/oftalma2016132410-19 (in Russian).

6. Saakyan S.V., Myakoshina E.B., Yurovskaya N.N. Tumor-associated distant maculopathy caused by small uveal melanoma. Russian ophthalmological journal. 2011; 2: 41–5 (in Russian).

7. Rootman D.B., Gonzalez E., Mallipatna A., et al. Hand-held high-resolution spectral domain optical coherence tomography in retinoblastoma: clinical and morphologic considerations. Br. J. Ophthalmol. 2013; 97: 59–65. doi: 10.1136/bjophthalmol-2012-302133

8. Cao C., Markovitz M., Ferenczy S., et al. Hand-held spectral-domain optical coherence tomography of small macular retinoblastoma in infants before and after chemotherapy. J. Pediatr. Ophthalmol. Strabismus. 2014; 51: 230–4. doi: 10.3928/01913913-20140603-01

9. Seider M.I., Grewal D.S., Mruthyunjaya P. Portable optical coherence tomography detection or confirmation of ophthalmoscopically invisible or indeterminate active retinoblastoma. Ophthalmic surgery. Lasers Imaging Retin. 2016; 47: 965–8. doi: 10.3928/23258160-20161004-12

10. Yousef Y.A., Shroff M., Halliday W., et al. Detection of optic nerve disease in retinoblastoma by use of spectral domain optical coherence tomography. JAAPOS. 2012; 16: 481–3. doi: 10.1016/j.jaapos.2012.05.010

11. Berry J.L., Cobrinik D., Kim J.W. Detection and intraretinal localization of an “invisible” retinoblastoma using optical coherence tomography. Ocul. Oncol. Pathol. 2015; 2: 148–152. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881267/

12. Hasanreisoglu M., Dolz-Marco R., Ferenczy S.R., et al. Spectral domain optical coherence tomography reveals hidden fovea beneath extensive vitreous seeding from retinoblastoma. Retina. 2015; 35: 1486–7. doi: 10.1097/IAE.0000000000000477

13. Maidana D.E., Pellegrini M., Shields J.A., et al. Choroidal thickness after intraarterial chemotherapy for retinoblastoma. Retina. 2014; 34: 2103–9. doi: 10.1097/IAE.0000000000000190

14. Samara W.A., Pointdujour-Lim R., Say E.A.T., et al. Foveal microanatomy documented by SD-OCT following treatment of advanced retinoblastoma. J. AAPOS. 2015; 19: 368–72.

15. Do J.L., Do B., Berry J.L. Optical coherence tomography for diagnosis and management of retinoblastoma. Advances in ophthalmology and optometry 2017; 2 (1): 101–18. doi: 10.1016/j.yaoo.2017.03.006

16. Neroev V.V., Saakyan S.V., Myakoshina E.B., et al. The first experience of using optical coherence tomography in the diagnosis of primary and residual r etinoblastoma. Vestnik oftal'mologii. 2012; 2: 8–12 (in Russian).

17. Saakyan S.V., Myakoshina E.B., Polyakov V.G., Ushakova T.L., Ismailova D.M. Maculopathy and chorioretinopathy in children with retinoblastoma receiving chemotherapy: clinical trials and morphometric analysis. Rossijskaya pediatricheskaya oftal’mologija. 2018; 13, 4: 167–75 (in Russian).

18. Saakyan S.V., Myakoshina E.B., Krichevskaya G.I., Slepova O.S. Retinoblastoma and “pseudoretinoblastoma” in children: clinical, tomographic and serological features. Vestnik oftal'mologii. 2014; 1: 18–24 (in Russian).

19. Saakyan S.V., Katargina L.A., Valskii V.V., et al. Federal clinical recommendations «Diagnostics, monitoring and treatment retinoblastoma». Rossijskaya Pediatricheskaya Oftal’mologija. 2015; 4: 43–8 (in Russian).

20. Saakyan S.V., Myakoshina E.B., Zaytseva O.V., Ryabina M.V. The method of differential diagnosis of different forms of primary initial retinoblastoma in children. Patent RF # 216.012.3586; 2013 (in Russian).

21. Saakyan S.V., Myakoshina E.B., Zaytseva O.V., Ryabina M.V., Tatskov R.A. Method of assessing efficiency of combined organ-preserving treatment of primary initial retinoblastoma in children. Patent RF # 2486859; 2013 (in Russian).

22. Shpak A.A., Ogorodnikova S.N. Diagnostic method for papilledema. Patent RF # 2486859; 2007 (in Russian).

23. Clinical guidelines: Atrophy of the optic nerve. Republic of Kazakhstan. Astana; 2016 (in Russian).

24. Said A.M.A., Elbayomi A.M., Shaat A.A.K. Structural changes of the macula and optic nerve head in the remaining eyes after enucleation for retinoblastoma: an optical coherence tomography study. BMC Ophthalmology. 2017; 17: 251. doi: 10.1186/s12886-017-0650-9